针对TGF-β和PD-L1的双特异性抗体用于协同癌症免疫治疗

相关实验视频

Updated: Jul 20, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Tianye Li^1,2, Xinrun Wang^1,2, Mengke Niu³

¹Department of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Frontiers in immunology

|July 31, 2023

概括

与新型双特异性抗体同时阻断TGF-β和PD-L1可以提高癌症免疫治疗的疗效. 这些下一代治疗方法有望克服对当前PD-1/PD-L1疗法的耐药性.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

编程细胞死亡蛋白1 (PD-1) /编程细胞死亡连接体1 (PD-L1) 途径是癌症免疫逃避的关键.
对抗PD-1/PD-L1疗法的低响应率和耐药性限制了临床成功.
过度表达的转化生长因子-β (TGF-β) 是癌症中另一个重要的免疫抑制因素.

研究的目的:

审查针对TGF-β和PD-L1.1两种特异性抗体的进展.
突出它们在克服对当前免疫疗法耐药性的潜力.
讨论它们在改变癌症治疗范式中的作用.

主要方法:

对双特异抗体进行的临床前和临床研究的综述.
专注于结合TGF-β和PD-L1阻断的抗体.
使用双特异抗体或融合蛋白技术.

主要成果:

同时阻断TGF-β和PD-L1可以增强抗瘤活性.
与单一疗法相比,双特异性抗体显示出更高的疗效.
这些药物有潜力克服抗PD-1/PD-L1治疗的抗药性.

结论:

针对TGF-β和PD-L1的双特异性抗体代表了下一代癌症免疫治疗的有希望的新一代.
它们提供了一种改善PD-1/PD-L1未被选择患者的应答率和克服耐药性的策略.
这些新型药物有望对癌症治疗模式产生重大影响.

关键词:

在PD-L1中.在TGF-β的基础上.两种特异性抗体的抗体癌症免疫疗法免疫疗法免疫检查点抑制剂免疫检查点抑制剂免疫疗法耐药性免疫疗法耐药性

更多相关视频

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...